Sensei Biotherapeutics (NASDAQ:FTH) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Sensei Biotherapeutics (NASDAQ:FTH) from a hold rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

A number of other analysts have also recently commented on the stock. Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. BTIG Research reissued a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. TD Cowen started coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, September 9th. They set a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.25.

Sensei Biotherapeutics Trading Down 3.6%

FTH opened at $28.00 on Friday. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14. The stock has a market cap of $723.52 million, a PE ratio of -0.20 and a beta of -0.28. The company has a 50 day moving average price of $32.07.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. Sell-side analysts predict that Sensei Biotherapeutics will post -13.69 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Brian C. Stephenson bought 5,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were purchased at an average cost of $23.50 per share, with a total value of $117,500.00. Following the completion of the purchase, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. The trade was a 11.99% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired 13,634 shares of company stock valued at $326,118 over the last 90 days. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new stake in Sensei Biotherapeutics during the 2nd quarter valued at about $307,000. Renaissance Technologies LLC raised its holdings in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the last quarter. Bank of America Corp DE raised its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics in the first quarter worth approximately $4,188,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics in the second quarter worth approximately $3,610,000. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.